GSK recalls popular heartburn medicine Zantac: U.K. medicines watchdog
GlaxoSmithKline Plc is recalling its heartburn medicine Zantac as a "precautionary measure" due to a probable cancer-causing impurity in the drug, Britain's medicines watchdog said on Tuesday.
The move follows the U.S. Food and Drug Administration discovery last week of "unacceptable levels" of a cancer-causing impurity in Zantac and its generic versions known chemically as ranitidine.
GSK is recalling all unexpired stock of Zantac from pharmacies due to possible contamination with an impurity N-nitrosodimethylamine (NDMA), the Medicines and Healthcare products Regulatory Agency (MHRA) said.
The company was not immediately available for a comment.